SEP
SUPN icon

Signature Equity Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Signature Equity Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698 Hold
15
– – ﹤0.01% 1380
2026
Q1 		$775 Sell
15
-105
-88% -$5.35K ﹤0.01% 1310
2025
Q4 		$5.96K Buy
+120
New +$5.83K ﹤0.01% 944

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Signature Equity Partners's SUPN Position: Q2 2026 in Review

Signature Equity Partners held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 15 shares worth $698. The position accounts for ﹤0.01% of the portfolio, ranked #1380.

Signature Equity Partners first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.96K in Q4 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Signature Equity Partners held 15 shares of Supernus Pharmaceuticals worth $698 as of Q2 2026.
  • Signature Equity Partners left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1380 holding.
  • Signature Equity Partners first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's Supernus Pharmaceuticals position peaked at $5.96K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.